Literature DB >> 30006736

Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.

Hildegard Kehrer-Sawatzki1, Lan Kluwe2, Reinhard E Friedrich3, Anna Summerer4, Eleonora Schäfer4, Ute Wahlländer5, Cordula Matthies6, Isabel Gugel7, Said Farschtschi2, Christian Hagel8, David N Cooper9, Victor-Felix Mautner2.   

Abstract

Schwannomatosis and neurofibromatosis type 2 (NF2) are both characterized by the development of multiple schwannomas but represent different genetic entities. Whereas NF2 is caused by mutations of the NF2 gene, schwannomatosis is associated with germline mutations of SMARCB1 or LZTR1. Here, we studied 15 sporadic patients with multiple non-intradermal schwannomas, but lacking vestibular schwannomas and ophthalmological abnormalities, who fulfilled the clinical diagnostic criteria for schwannomatosis. None of them harboured germline NF2 or SMARCB1 mutations as determined by the analysis of blood samples but seven had germline LZTR1 variants predicted to be pathogenic. At least two independent schwannomas from each patient were subjected to NF2 mutation testing. In five of the 15 patients, identical somatic NF2 mutations were identified (33%). If only those patients without germline LZTR1 variants are considered (n = 8), three of them (37.5%) had mosaic NF2 as concluded from identical NF2 mutations identified in independent schwannomas from the same patient. These findings imply that a sizeable proportion of patients who fulfil the diagnostic criteria for schwannomatosis, are actually examples of mosaic NF2. Hence, the molecular characterization of tumours in patients with a clinical diagnosis of schwannomatosis is very important. Remarkably, two of the patients with germline LZTR1 variants also had identical NF2 mutations in independent schwannomas from each patient which renders differential diagnosis of LZTR1-associated schwannomatosis versus mosaic NF2 in these patients very difficult.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30006736     DOI: 10.1007/s00439-018-1909-9

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  52 in total

1.  Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis.

Authors:  Miriam J Smith; Andrew J Wallace; Naomi L Bowers; Cecilie F Rustad; C Geoff Woods; Guy D Leschziner; Rosalie E Ferner; D Gareth R Evans
Journal:  Neurogenetics       Date:  2012-03-22       Impact factor: 2.660

2.  A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.

Authors:  J A Trofatter; M M MacCollin; J L Rutter; J R Murrell; M P Duyao; D M Parry; R Eldridge; N Kley; A G Menon; K Pulaski
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

3.  Germline mutations in the neurofibromatosis type 2 tumour suppressor gene.

Authors:  D Bourn; S A Carter; S Mason; D Gareth; R Evans; T Strachan
Journal:  Hum Mol Genet       Date:  1994-05       Impact factor: 6.150

4.  SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis.

Authors:  Guillaume Rousseau; Tetsuro Noguchi; Violaine Bourdon; Hagay Sobol; Sylviane Olschwang
Journal:  BMC Neurol       Date:  2011-01-24       Impact factor: 2.474

5.  Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification.

Authors:  D Gareth R Evans; R T Ramsden; A Shenton; C Gokhale; N L Bowers; S M Huson; G Pichert; A Wallace
Journal:  J Med Genet       Date:  2007-02-16       Impact factor: 6.318

6.  Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis.

Authors:  K D Hadfield; W G Newman; N L Bowers; A Wallace; C Bolger; A Colley; E McCann; D Trump; T Prescott; D G R Evans
Journal:  J Med Genet       Date:  2008-02-19       Impact factor: 6.318

7.  Mutational analysis of patients with neurofibromatosis 2.

Authors:  M MacCollin; V Ramesh; L B Jacoby; D N Louis; M P Rubio; K Pulaski; J A Trofatter; M P Short; C Bove; R Eldridge
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

8.  Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.

Authors:  Miriam J Smith; Naomi L Bowers; Michael Bulman; Carolyn Gokhale; Andrew J Wallace; Andrew T King; Simon K L Lloyd; Scott A Rutherford; Charlotte L Hammerbeck-Ward; Simon R Freeman; D Gareth Evans
Journal:  Neurology       Date:  2016-11-16       Impact factor: 9.910

9.  Genetic and epigenetic alterations of the NF2 gene in sporadic vestibular schwannomas.

Authors:  Jong Dae Lee; Tae Jun Kwon; Un-Kyung Kim; Won-Sang Lee
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

10.  Segmental neurofibromatosis type 2: discriminating two hit from four hit in a patient presenting multiple schwannomas confined to one limb.

Authors:  Elisabeth Castellanos; Isabel Bielsa; Cristina Carrato; Imma Rosas; Ares Solanes; Cristina Hostalot; Emilio Amilibia; José Prades; Francesc Roca-Ribas; Conxi Lázaro; Ignacio Blanco; Eduard Serra
Journal:  BMC Med Genomics       Date:  2015-01-24       Impact factor: 3.063

View more
  8 in total

Review 1.  Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Authors:  Shivani Ahlawat; Jaishri O Blakeley; Shannon Langmead; Allan J Belzberg; Laura M Fayad
Journal:  Skeletal Radiol       Date:  2019-08-08       Impact factor: 2.199

2.  From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.

Authors:  Rosalie E Ferner; Annette Bakker; Ype Elgersma; D Gareth R Evans; Marco Giovannini; Eric Legius; Alison Lloyd; Ludwine M Messiaen; Scott Plotkin; Karlyne M Reilly; Aaron Schindeler; Miriam J Smith; Nicole J Ullrich; Brigitte Widemann; Larry S Sherman
Journal:  Am J Med Genet A       Date:  2019-03-25       Impact factor: 2.802

Review 3.  Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis.

Authors:  Vanessa L Merker; Bronwyn Slobogean; Justin T Jordan; Shannon Langmead; Mark Meterko; Martin P Charns; A Rani Elwy; Jaishri O Blakeley; Scott R Plotkin
Journal:  Am J Med Genet A       Date:  2022-06-09       Impact factor: 2.578

4.  Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysis.

Authors:  Umberto Tosi; Omri Maayan; Anjile An; Miguel E Tusa Lavieri; Sergio W Guadix; Antonio P DeRosa; Paul J Christos; Susan Pannullo; Philip E Stieg; Andrew Brandmaier; Jonathan P S Knisely; Rohan Ramakrishna
Journal:  J Neurooncol       Date:  2022-01-18       Impact factor: 4.130

5.  Age-related schwannomatosis with potential exosome-mediated contribution to prostate hyperplasia: a case report and mini-review.

Authors:  Bérengère Chignon-Sicard; Véronique Hofman; Daniel Chevallier; Jean-Michel Cucchi; Marius Ilié; Bérengère Dadone-Montaudié; Florence Paul; Xavier Carpentier; Hervé Quintens; Coraline Bence-Gauchiez; Didier Caselles; Jacqueline Rossant; Matthieu Durand; Roger Bertolotti
Journal:  Ther Adv Urol       Date:  2019-09-26

6.  Comparison of the frequency of loss-of-function LZTR1 variants between schwannomatosis patients and the general population.

Authors:  Fanxuan Deng; D Gareth Evans; Miriam J Smith
Journal:  Hum Mutat       Date:  2022-04-14       Impact factor: 4.700

7.  ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis.

Authors:  D Gareth Evans; Stefania Mostaccioli; David Pang; Mary Fadzil O Connor; Melpo Pittara; Nicolas Champollion; Pierre Wolkenstein; Nick Thomas; Rosalie E Ferner; Michel Kalamarides; Matthieu Peyre; Laura Papi; Eric Legius; Juan Luis Becerra; Andrew King; Chris Duff; Stavros Stivaros; Ignacio Blanco
Journal:  Eur J Hum Genet       Date:  2022-04-01       Impact factor: 5.351

8.  Screening of potential novel candidate genes in schwannomatosis patients.

Authors:  Cristina Perez-Becerril; Andrew J Wallace; Helene Schlecht; Naomi L Bowers; Philip T Smith; Carolyn Gokhale; Helen Eaton; Chris Charlton; Rachel Robinson; Ruth S Charlton; D Gareth Evans; Miriam J Smith
Journal:  Hum Mutat       Date:  2022-06-27       Impact factor: 4.700

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.